Just days ahead of a Parliamentary vote on a Brexit deal, the U.K. government announced Wednesday a second deal for life sciences that comprises mostly industry investment into the U.K. spearheaded by a £1 billion ($1.3 billion) investment by Belgian pharma UCB S.A. (Euronext:UCB) over the next five years.